Ignite Creation Date:
2024-05-06 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 2:22 PM
Study NCT ID:
NCT05194163
Status:
NOT_YET_RECRUITING
Last Update Posted:
2022-03-29
First Post:
2022-01-13
Brief Title:
MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimers Disease
Sponsor:
Neurokine Therapeutics
Organization:
Neurokine Therapeutics
Study Overview
Official Title:
A Phase 2a Study of MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimers Disease
Status:
NOT_YET_RECRUITING
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SKI-AD
Brief Summary:
This study is a phase 2a randomized double-blind placebo-controlled study in mild-to-moderate Alzheimers disease of the oral investigational drug MW150 a p38alphaMAPK kinase inhibitor The primary goals of this study are to investigate the safety and tolerability and drug movements in the body The secondary goals of the study are to investigate the effects of the drug on cognitive performance activities of daily living and behavior and the biological effects of the drug on blood biomarkers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R44AG071388 | NIH | None | httpsreporternihgovquickSearchR44AG071388 |